CombiMatrix Molecular Diagnostics | GenomeWeb
CombiMatrix Molecular Diagnostics last week launched its melanoma test, a diagnostic that it claims can discriminate malignant melanoma from benign moles.

The expression-based test, which runs on CombiMatrix’s CustomArray platform, could enable pathologists to resolve difficult-to-diagnose cases through an objective genetic analysis, CMDX parent CombiMatrix said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.